secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2024-01-29T23:59:59+00:00
Accession:  0001104659-24-007712
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem outlines 2024 priorities: NDA submission for avutometinib/defactinib in LGSOC in H1 2024
--------------------------------------------------------------------------------

- Plans to begin rolling NDA submission for accelerated approval of avutometinib/defactinib in recurrent LGSOC in H1 2024; potential commercial launch in 2025.
- Initial data from RAMP 205 trial of avutometinib/defactinib plus chemo in frontline metastatic pancreatic cancer expected H1 2024.
- Data from RAMP 203 and RAMP 204 trials in KRAS G12C-mutant NSCLC planned for mid-2024.
- Interim RAMP 201 results showed ORR 45% (13/29) and disease control 86% (25/29) in LGSOC; Phase 3 RAMP 301 initiated.
- Collaborator GenFleet to advance oral KRAS G12D inhibitor GFH375/VS-7375 into Phase 1 in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000110465924007712/0001104659-24-007712-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000110465924007712/tm244111d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-007712

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer